Published on BreakingExpress:
Institutional news release — University of Cape Town
By Stephen Langtry. Originally published November 19, 2026. Original source · Reuse terms. Text-only republication; media omitted.
In Ekurhuleni, east of Johannesburg, Professor Ian Ross sat on a cooler box packed with ice. He had driven there on a weekend to examine a patient with Addison’s disease, one of many such journeys to towns and townships across the country.
“Patients remarked that it was the first time that somebody took an interest in their disease,” he recalled. Many had very little. Yet without exception, he said, they offered him the cleanest towels in the house and something from their makeshift kitchens.
Professor Ross, a specialist in the Division of Endocrinology and Diabetology at the University of Cape Town (UCT) and Groote Schuur Hospital, described those journeys on Thursday, 12 November 2026, when he delivered his inaugural lecture, “The dichotomous effects of cortisol and what we have learned from hypoadrenalism”, in the New Learning Centre Lecture Theatre on the health sciences campus. “I’m a full-time clinician, a regular teacher and an after-hours researcher,” he said.
Two faces of one hormone
Cortisol is usually discussed as a stress hormone, and Ross acknowledged the harm it can do. Chronic stress keeps cortisol levels high, disturbing sleep, concentration and mood, raising blood sugar and adding fat around the waist. He cited evidence that meditation lowers cortisol and quietens the brain’s fear centre.
But to think of cortisol only in those terms, he said, is a mistake. It maintains blood sugar during fasting, restrains inflammation, protects tissue from damage, supports blood pressure and heart function, and regulates sleep, cognition and emotion. Almost every cell in the body carries a receptor for it.
Ross compared the two adrenal glands, which sit above the kidneys and produce nearly all of the body’s cortisol, to the twin engines of an aircraft. A plane can fly on one engine; a person can stay healthy with one working adrenal gland. The trouble begins when both fail.
Too much cortisol causes Cushing’s syndrome. Too little causes primary hypoadrenalism, or Addison’s disease: fatigue, salt craving, weight loss, dizziness and a darkening of the skin. With a worldwide prevalence of about 150 per million, Ross said, it is “by no means a rare disease”.
“I became interested in this condition [after] realising that many patients are dying without the diagnosis of it ever being made,” Ross said. He had also seen that patients close to death could dramatically improve with the right treatment.
Unusually for a doctoral candidate, Ross chose his own PhD topic, telling his then head of division, Professor Naomi Levitt, that he wished to study Addison’s disease in South Africa.
An office like a post office
Finding patients was the first hurdle: many South African hospitals keep no record of diagnoses. Ross built a database of public and private facilities and sent more than 10 000 personalised letters and some 9 600 emails to specialists, general practitioners and paediatricians, asking whether they treated anyone with the condition. “My office resembled the general post office,” he said. So began the South African Addison’s Disease Study.
Blood samples travelled on dry ice to UCT, and onward, frozen at –80 °C, to collaborators in Sweden and the United States. Ross became, in his words, “a reluctant logistics agent”. One consignment went missing for 10 days in a snowstorm before turning up in a warehouse in Washington, DC. A senior clinician with no laboratory experience, he learnt bench work from an honours student 18 years his junior.
In a cohort of 148 patients, signs of adrenal crisis at diagnosis – collapse, loss of consciousness and shock – were more common than in cohorts elsewhere, suggesting that South Africans are diagnosed later than their European counterparts. About half had autoimmune disease; 8% had tuberculosis.
“It takes a special person to make cortisol interesting.”
The team was the first to show that patients with Addison’s disease have a markedly worse cholesterol profile than matched healthy controls, pointing to serious cardiovascular risk, and South African patients fared worse than Swedish patients. Many were also taking more hydrocortisone than the body would naturally produce. Ross urged doctors to keep a low threshold for starting cholesterol-lowering treatment.
Later studies found testosterone deficiency in a third of male patients and premature ovarian failure in 11% of women; poorer sleep, with less deep sleep, which in turn lowered mood and memory; and a genetic variant that makes some patients need higher doses, opening the way to personalised treatment. During the pandemic, patients with Addison’s disease proved three times as likely to contract COVID-19 and almost 20 times as likely to be hospitalised.
Patients must raise their doses during illness, surgery or stress to avert an adrenal crisis. A comparison with patients in the United Kingdom (UK) found gaps in knowledge in both countries, but wider ones here: faced with a dental procedure, 62% of South African respondents would not have adjusted their medication, against 8% in the UK.
“Why does this matter? Because not increasing when ill can lead to adrenal crisis, which has a significant mortality attached to it,” Ross said.
‘I am never cross’
Introducing Ross, Professor Mashiko Setshedi, head of UCT’s Department of Medicine, noted his more than 70 peer-reviewed publications, his C2 rating from the National Research Foundation and his standing among the most published authors on Addison’s disease worldwide. He was the first recipient of the certificate in endocrinology in South Africa. She also paid tribute to his advocacy for the dignity of intersex and transgender people; and to the registrars who in 2019 voted him the consultant with the best bedside manner in the department.
“Ian saved my life.”
Professor Joel Dave, head of the Division of Endocrinology, sent his tribute by video from Zimbabwe. He recalled Ross spending thousands of rands of his own money on protective equipment at the start of the COVID-19 pandemic and noted that Ross answers every enquiry after his health with “Oh, struggling along.” Professor Dave said: “If this is what struggling looks like, I think the rest of us have some serious catching up to do.”
Professor Marc Blockman, who has worked with Ross on ethics and medicines committees, observed that “it takes a special person to make cortisol interesting”, and quoted the reassurance Ross offers trainees: “I want you to know, I am never cross.”
Deputy Vice-Chancellor for People, Culture and Society Professor Elelwani Ramugondo, who welcomed guests, closed the formal tributes with a personal disclosure. In the early 2000s, she said, Ross identified the blood-sugar condition behind her fainting spells and taught her to manage it. “Ian saved my life.”
In his closing remarks, Professor Lionel Green-Thompson, dean of the Faculty of Health Sciences, reflected on the photographs of Ross’s fieldwork. They were less about cortisol, he said, than about “taking the science to people and bringing the people into our scientific conversation”.
In all his years at Groote Schuur Hospital, Ross said, the greatest compliment he has received is that the last patient of the day gets the same care as the first.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Please view the republishing articles page for more information.